R&D News | pharmaphorum

News

Neurogene falls again on Rett gene therapy side effects

Neurogene has halted patient enrolment in the high-dose arm of its trial of Rett syndrome gene therapy, sparking another run on its shares.

News

AbbVie bags EU nod for key drug from ImmunoGen takeover

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically cleared for folate receptor-alpha (FRα) positive, platinum-resistant

News

female scientist conducting experiment in a laboratory

Tirzepatide gets a big win in obesity-related heart failure

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the

News

Trump pick of RFK for top US health job astounds critics

Last night, news broke that President-Elect Donald Trump had nominated Robert F Kennedy Jr (aka RFK Jr) as US Health Secretary.

News

MSD joins PD-1/VEGF push in cancer with LaNova deal

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy.

News

Syncona aims Slingshot at biotech's 'translational gap'

UK-based life science investor Syncona has launched a new company – Slingshot Therapeutics – with a mission to find promising projects in academia and translate them into full-blown develop

Neurogene falls again on Rett gene therapy side effects

AbbVie bags EU nod for key drug from ImmunoGen takeover

Tirzepatide gets a big win in obesity-related heart failure

Trump pick of RFK for top US health job astounds critics

MSD joins PD-1/VEGF push in cancer with LaNova deal

Syncona aims Slingshot at biotech's 'translational gap'

FDA kicks off review of Takeda's narcolepsy hopeful

How to meet your physicians where they are online

News

Editor's Picks